Eli Lilly (LLY) closed Friday at a $1.27 trillion market capitalization, positioning the drugmaker within striking distance of Tesla's $1.4 trillion valuation and squarely in view of CNBC's Jim Cramer's $2 trillion target. That bullish call implies $730 billion in upside from Friday's close.
Cramer's projection rests on two pillars: explosive earnings growth and the sheer addressable market for GLP-1 drugs. CEO Dave Ricks recently signaled that Lilly's ongoing studies suggest approximately 15 percent of the population could benefit from GLP-1 medications, a market far larger than current penetration rates.
The numbers back the growth narrative. Third-quarter revenue rose 39 percent to $24.4 billion, prompting management to raise its 2026 revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion. Mounjaro, Lilly's diabetes drug, posted 65 percent growth to $10.7 billion in quarterly sales. Zepbound, its obesity treatment, jumped 49 percent to $5.4 billion.
Analysts on TIKR expect normalized EPS to more than double from $24.21 in 2025 to $57.78 by 2028, capping a quadrupling from $6.32 in 2023. Total revenue is projected to reach $119 billion by 2028, up from $65.2 billion in 2025.
The strategic catalyst arrived Friday with Lilly's partnership with Hims Hers Health (HIMS). The telehealth platform will now directly sell Lilly's obesity drugs—Foundayo at $149 monthly and Zepbound at $299—matching LillyDirect pricing. The deal includes a clause barring Hims from selling compounded versions of Lilly's medications.
This move matters because 40 to 45 percent of Zepbound sales already come from self-pay customers, a channel Hims dominates. Lilly is playing catch-up with rival Novo Nordisk, which has distributed Wegovy and Ozempic through Hims since March. The new arrangement expands Lilly's reach into the direct-to-consumer telehealth channel without sacrificing price control.
Lilly's competitive position remains formidable. Management reports its drugs command approximately 60 percent of U.S. obesity drug prescriptions—commanding share that should sustain pricing power even as the market expands.
Valuation arithmetic reveals the path to $2 trillion. At the current 29x forward earnings multiple—below its five-year average of 40x and sharply compressed from its October 2023 peak of 67x—Lilly's projected 2028 EPS of $57.78 values the stock at roughly $1.6 trillion. That leaves a $400 billion gap to Cramer's $2 trillion target, requiring multiple expansion to either 35x or lower EPS estimates to miss.
For equity holders, the bull case hinges on two developments: whether Hims distribution materially accelerates GLP-1 penetration beyond current self-pay adoption, and whether the obesity indication's addressable market justifies 40x-plus valuations on 2028 earnings. Current 29x pricing suggests the Street is pricing in deceleration or meaningful competition by 2028—a bet worth testing against Lilly's 60 percent market share and pipeline strength.
